Moreover, the recent discovery that the STING/IFN-β-signaling pathway is linked to the pathology of EAE and possibly MS is strengthened by the fact that its specific activation leads to an improved clinical EAE course by inducing an IFN type I response [30,31,32]. This evidence concerns the gene IFNB1 and myeloid sarcoma.